Santa Barbara, CA – November 4, 2014 – Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced yesterday the closing of its initial public offering of 5,750,000 shares of common stock at a price to the public of $15.00 per share, which includes 750,000 shares purchased pursuant to the exercise in full of the underwriters’ option to purchase additional shares. Sientra received approximately $80.2 million in aggregate net proceeds, after deducting underwriting discounts and commissions. Sientra’s common stock commenced trading on the NASDAQ Global Select Market under the ticker symbol “SIEN” on October 29, 2014.
Piper Jaffray and Stifel acted as joint book-running managers for the offering. Leerink Partners and William Blair acted as co-managers.
The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, and by e-mail at firstname.lastname@example.org; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at email@example.com.
A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
The Ruth Group